Skip to Main Content

Paper Details

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Lung Cancer
9
2022
Author NameAffiliation
Geoffrey LiuPrincess Margaret Cancer Centre, University of Toronto
Benjamin SolomonPeter MacCallum Cancer Centre
  • 1 - 2

Datasets

Release 1.2